Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (244 reviews)

For research use only.

Catalog No.S1011

244 publications

CAS No. 850140-72-6

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 244 publications

Nature, 2020, 584(7822):608-613

PubMed: 32848220 ( click the link to review the publication )

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )
Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, 1;AAC.00341-20

PubMed: 32482675 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Korean J Parasitol, 2020, 58(3):249-255

PubMed: 32615738 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Genome Biol, 2020, 21(1):181

PubMed: 32727536 ( click the link to review the publication )
J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Oncoimmunology, 2019,

PubMed: 30713780 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )
Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9):e8746

PubMed: 30021798 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29880898 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )
Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(47):6581-6591

PubMed: 28783173 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )
Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28881811 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )
Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27799141 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )
Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Discov, 2015,

PubMed: 26243863 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015,

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25537503 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )
Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )
Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M1qxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTaR3M4UUN3ME2wMlAxPTd{IN88US=>	M1nSPHNCVkeHUh?=
KASUMI-1	NV;sZ4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzRVI1KSzVyPUCuNFA6OTFizszN	NWfUV3g3W0GQR1XS
HCC2218	NYHidGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLI[nhWUUN3ME2wMlAxQTh5IN88US=>	NX2yeZl[W0GQR1XS
KARPAS-45	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33sZ2lEPTB;MD6wNVY4OSEQvF2=	NIn3cIxUSU6JRWK=
HSC-4	NV3n[pQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nVVmlEPTB;MD6wNVc1QCEQvF2=	MnzUV2FPT0WU
CHL-1	NHrPSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2KxRWlEPTB;MD6wNVg{QSEQvF2=	MmLaV2FPT0WU
KY821	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDMTWM2OD1yLkCyNFYh\|ryP	MnzCV2FPT0WU
NCI-N87	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3TeZhUUUN3ME2wMlAzPzd\|IN88US=>	NUiySVkxW0GQR1XS
DOK	M3r1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjxRoVKSzVyPUCuNFMyQTRizszN	Mo\SV2FPT0WU
DSH1	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\JTWM2OD1yLkCzN\|E1KM7:TR?=	Mm\WV2FPT0WU
MDA-MB-175-VII	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEO0NVYh\|ryP	NW\QemZOW0GQR1XS
NCI-H2170	M4DCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr6XY5iUUN3ME2wMlA{PzJ6IN88US=>	M{juZXNCVkeHUh?=
BT-474	NVv1cJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMES5PFYh\|ryP	NUHv[XFGW0GQR1XS
EFO-27	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn2TWM2OD1yLkC1NVgzKM7:TR?=	NX7CUYxmW0GQR1XS
NCI-H720	M3\jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMEWzNlUh\|ryP	NWK5doU5W0GQR1XS
PC-14	M3vl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHiTWM2OD1yLkC1OlY5KM7:TR?=	MYPTRW5ITVJ?
EC-GI-10	NFyxO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLSdYZHUUN3ME2wMlA2QTF{IN88US=>	MVjTRW5ITVJ?
KYSE-450	NXrUTIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTZTWM2OD1yLkC1PVc5KM7:TR?=	MVfTRW5ITVJ?
BPH-1	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX3TWM2OD1yLkC1PVg5KM7:TR?=	Mm\kV2FPT0WU
NCI-H292	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwME[wPUDPxE1?	NE\JbVRUSU6JRWK=
H9	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX6TWM2OD1yLkC3NVMzKM7:TR?=	M17oc3NCVkeHUh?=
NCI-H526	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7D[FhKSzVyPUCuNFc5OjNizszN	MV3TRW5ITVJ?
NCI-H1623	M13qWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TCdWlEPTB;MD6wPFAzPSEQvF2=	NU\oR3JGW0GQR1XS
KYSE-140	NIe3XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMEizN{DPxE1?	MoTKV2FPT0WU
Ca9-22	M3[1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonITWM2OD1yLkC4N\|U{KM7:TR?=	NHzxUmhUSU6JRWK=
AU565	NGDySXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjTWZlrUUN3ME2wMlA5PTB2IN88US=>	Ml\oV2FPT0WU
ZR-75-30	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlntTWM2OD1yLkC5OVQ2KM7:TR?=	M4TLZXNCVkeHUh?=
NCI-H1770	NI\4XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMUCyPEDPxE1?	NUfqb\|RYW0GQR1XS
LB2241-RCC	M2HEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljzTWM2OD1yLkGwPFg1KM7:TR?=	M4m2OnNCVkeHUh?=
CAL-39	NVvtV21zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSzUmlKSzVyPUCuNVE4QTJizszN	MYPTRW5ITVJ?
UACC-893	NWXXNmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3zXG5KSzVyPUCuNVE5QDVizszN	MmX6V2FPT0WU
LU-65	M1;UXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzVVHFKSzVyPUCuNVI3OzNizszN	M1OydHNCVkeHUh?=
HN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7kepBKSzVyPUCuNVMxPzdizszN	MVfTRW5ITVJ?
TI-73	NFPIcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jxTmlEPTB;MD6xOFcyPSEQvF2=	M4PUbnNCVkeHUh?=
KU812	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\kZXJKSzVyPUCuNVU1PTZizszN	NWD3Z2pXW0GQR1XS
SW13	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMU[yNVYh\|ryP	NFfqVWdUSU6JRWK=
BB30-HNC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3W1V2lEPTB;MD6xOlU4PiEQvF2=	NYrzTWpVW0GQR1XS
HSC-2	NHLx[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PNZ2lEPTB;MD6xOlg{PyEQvF2=	MXXTRW5ITVJ?
BV-173	NYXoXI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTBTWM2OD1yLkG3OVk3KM7:TR?=	MWXTRW5ITVJ?
CAL-27	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPST2FKSzVyPUCuNVc3OzZizszN	NFjBPINUSU6JRWK=
SBC-1	M3znWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1O4ZmlEPTB;MD6xPFk2QSEQvF2=	NUHaZ4V5W0GQR1XS
CAL-33	M{eybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMkCxPFQh\|ryP	NWfwXmJsW0GQR1XS
NCI-H209	NVHlWGprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfWTWM2OD1yLkKwOFYh\|ryP	NUfoXpltW0GQR1XS
COR-L105	M1naemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojUTWM2OD1yLkKxNFg1KM7:TR?=	M1;jOnNCVkeHUh?=
HSC-3	NV60[lJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXvRXNKSzVyPUCuNlEyQThizszN	MYrTRW5ITVJ?
NCI-H69	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln5TWM2OD1yLkKxOFUyKM7:TR?=	MXrTRW5ITVJ?
MOLT-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMkO5O\|Uh\|ryP	NGmwUVRUSU6JRWK=
ML-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF31NG9KSzVyPUCuNlQ5ODJizszN	NG\BS\|hUSU6JRWK=
IGROV-1	M33wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK0XJBKSzVyPUCuNlU6PTJizszN	NF3yUIJUSU6JRWK=
TK10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMk[3N\|gh\|ryP	NXPjcI02W0GQR1XS
EoL-1-cell	NIm3UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfrTWM2OD1yLkK2PFkzKM7:TR?=	MYTTRW5ITVJ?
HO-1-N-1	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDyTWM2OD1yLkK3PFU{KM7:TR?=	MVzTRW5ITVJ?
BHY	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jibGlEPTB;MD6yPFY2PSEQvF2=	NYqyRXJDW0GQR1XS
LU-139	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrXTWM2OD1yLkOwOVEh\|ryP	MorEV2FPT0WU
23132-87	M3[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwM{G5NlMh\|ryP	NUnVcIRmW0GQR1XS
ACHN	M4L5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n4[WlEPTB;MD6zNVk6PCEQvF2=	MXPTRW5ITVJ?
DoTc2-4510	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfrTWM2OD1yLkOyNlE6KM7:TR?=	Ml6wV2FPT0WU
BB65-RCC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LZO2lEPTB;MD6zOFU6OyEQvF2=	MnPCV2FPT0WU
HLE	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG2TWM2OD1yLkO1NFQ3KM7:TR?=	NXfXR\|A1W0GQR1XS
HCC1419	NHjjeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTCTGxKSzVyPUCuN\|Y1ODhizszN	M4n3NnNCVkeHUh?=
A388	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwM{[4OVch\|ryP	MnqxV2FPT0WU
NUGC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPLcpRpUUN3ME2wMlM5Ozd\|IN88US=>	MUDTRW5ITVJ?
KYSE-180	M1fDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvnNYpKSzVyPUCuN\|kxQDlizszN	NWGzdJVlW0GQR1XS
TE-6	NXPFbJF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLjXoZ{UUN3ME2wMlQxOjR4IN88US=>	NGr6S\|dUSU6JRWK=
A498	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwNEC2O\|Qh\|ryP	M2jBWXNCVkeHUh?=
NCI-H1648	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn64TWM2OD1yLkS0NVgzKM7:TR?=	MV;TRW5ITVJ?
DU-145	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorqTWM2OD1yLkS0PFM{KM7:TR?=	M3LrbXNCVkeHUh?=
CW-2	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2flOWlEPTB;MD60OlkyPCEQvF2=	NWLmfVQ6W0GQR1XS
A431	NGDnOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT5d\|BEUUN3ME2wMlQ5OjN\|IN88US=>	NUC2Z\|Q1W0GQR1XS
SAS	M3i5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNEizPVgh\|ryP	MnvEV2FPT0WU
NCI-H2126	M4TDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPheZBXUUN3ME2wMlUyQTJ4IN88US=>	MUTTRW5ITVJ?
NCI-H358	NUjsc5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjuSG5KSzVyPUCuOVMzOSEQvF2=	NUG1VJBJW0GQR1XS
FADU	NEPWUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;XfXY5UUN3ME2wMlU1PDB2IN88US=>	MVrTRW5ITVJ?
ACN	M4jLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7rTWM2OD1yLkW1NFk1KM7:TR?=	M{\uZ3NCVkeHUh?=
HCC70	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPKfmV6UUN3ME2wMlU4PjZzIN88US=>	NGP1ZXFUSU6JRWK=
NCI-H1838	M1\QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwNkCyPVkh\|ryP	NYnDfVYzW0GQR1XS
CAL-54	M3zZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwNkG2NlEh\|ryP	MkOyV2FPT0WU
NCI-H1975	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwNkG3Nlgh\|ryP	MkPIV2FPT0WU
COR-L88	NGjMfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLlTWM2OD1yLk[0NVE{KM7:TR?=	NW[zVoZkW0GQR1XS
CTV-1	NHHTfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[xTWM2OD1yLk[0N\|kzKM7:TR?=	NGHzeo9USU6JRWK=
EW-18	M{G1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwNki2PVgh\|ryP	NXzCOlV6W0GQR1XS
HCC1806	NHXKeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33qfWlEPTB;MD62PVY3PiEQvF2=	MkXqV2FPT0WU
HuP-T4	NXfQ[WU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNkm3OkDPxE1?	MkPoV2FPT0WU
MDA-MB-361	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z0SmlEPTB;MD63NlY3OiEQvF2=	M1fXS3NCVkeHUh?=
NCI-H1573	M{i0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorwTWM2OD1yLkezOlMh\|ryP	NGTNT2JUSU6JRWK=
KU-19-19	NFnQ[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqzco5KSzVyPUCuO\|c1PjRizszN	MkfmV2FPT0WU
COLO-678	NVj6XHE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTDTWM2OD1yLkiwPFM1KM7:TR?=	MonDV2FPT0WU
C-33-A	M2jaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjJboJKSzVyPUCuPFEzQTdizszN	NX\ZcpJNW0GQR1XS
Calu-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NID0bZRKSzVyPUCuPFE1OzRizszN	MmLNV2FPT0WU
AGS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fM[WlEPTB;MD64N\|Y1QCEQvF2=	MUjTRW5ITVJ?
SCC-25	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPwVHpKSzVyPUCuPFQyPzFizszN	MkK1V2FPT0WU
JVM-2	NFXj[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHCc3pRUUN3ME2wMlg5Ojl7IN88US=>	M4r2W3NCVkeHUh?=
HCE-T	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rW[GlEPTB;MD64PFQzQCEQvF2=	MXvTRW5ITVJ?
ES4	M{WwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7hXlBOUUN3ME2wMlk4QDN4IN88US=>	M2nmSHNCVkeHUh?=
EKVX	NYrkeHRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnhdplRUUN3ME2xMlAyODZ2IN88US=>	NULnN2JJW0GQR1XS
D-542MG	NYjU[\|lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof1TWM2OD1zLkCxNFY1KM7:TR?=	MnrFV2FPT0WU
SW1116	MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrYSoN[UUN3ME2xMlAyOjh5IN88US=>	NEW0T4ZUSU6JRWK=
5637	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTFwMEG1NUDPxE1?	NInJSG5USU6JRWK=
HT-1376	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTFwMEG1NVMh\|ryP	NEjSdG5USU6JRWK=
NB69	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHVTWM2OD1zLkCyPVQ2KM7:TR?=	NFPKfFVUSU6JRWK=
YKG-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTZTWM2OD1zLkC1OFE6KM7:TR?=	NHLkOWpUSU6JRWK=
EW-3	NIfhT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTFwMEe4PFMh\|ryP	NEnYT\|RUSU6JRWK=
GCIY	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwMEixNFQh\|ryP	MkDqV2FPT0WU
SK-MES-1	NUfDe4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFwMUG0PFch\|ryP	MmfCV2FPT0WU
PANC-08-13	NWPCeZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFwMU[0NVYh\|ryP	NFvuU2FUSU6JRWK=
SK-NEP-1	NVK0SnB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFwMUe1NVMh\|ryP	Mn3sV2FPT0WU
SW954	NGXnWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PhemlEPTB;MT6yNFIyPCEQvF2=	NELqUGZUSU6JRWK=
NCI-SNU-5	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnKTWM2OD1zLkKzPUDPxE1?	NHzOb3dUSU6JRWK=
SW48	M2XUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknFTWM2OD1zLkK1OFMzKM7:TR?=	Mlv2V2FPT0WU
HT-3	NHjsNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFwMki3OVMh\|ryP	M3rFd3NCVkeHUh?=
ETK-1	M3HPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\lTWM2OD1zLkO3OFU3KM7:TR?=	NXfuSVF2W0GQR1XS
SCC-15	M3u5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjWWFdKSzVyPUGuN\|k1PTFizszN	NUHNVlBCW0GQR1XS
DU-4475	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwNECxNlEh\|ryP	NFjifXRUSU6JRWK=
NB5	NFvleYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHsWWRKSzVyPUGuOFE{OTdizszN	NGDQUZhUSU6JRWK=
CFPAC-1	NYjsd3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\jeI1KSzVyPUGuOFI1QTNizszN	NHXvW5dUSU6JRWK=
NCI-H630	NIG3cWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC0VVlKSzVyPUGuOFU2QDJizszN	NEi4N5dUSU6JRWK=
NCI-H82	NYn3[pZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTFwNUSwNFYh\|ryP	M2n2WHNCVkeHUh?=
ECC10	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwNUWzOlkh\|ryP	NWfIXXV4W0GQR1XS
K5	M1P0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYWz[pJsUUN3ME2xMlU5OzV5IN88US=>	NWSzd49pW0GQR1XS
ME-180	M2XFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HmNWlEPTB;MT62NVA6PiEQvF2=	MYPTRW5ITVJ?
KYSE-410	NYnaOHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGCxfWRKSzVyPUGuOlU3PzJizszN	MWrTRW5ITVJ?
G-401	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTFwNke0NVMh\|ryP	NVu0cm83W0GQR1XS
TGBC24TKB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP6S5pKSzVyPUGuOlgzOyEQvF2=	M4WzcHNCVkeHUh?=
Detroit562	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PEXGlEPTB;MT63NFE2OiEQvF2=	MVXTRW5ITVJ?
OE19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPQ[25lUUN3ME2xMlcyPTF{IN88US=>	MmfMV2FPT0WU
CAKI-1	NHK4c3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLZd\|lKSzVyPUGuO\|gzOTFizszN	MoHKV2FPT0WU
TE-12	M{GyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7Qb\|FKSzVyPUGuPFA1OTRizszN	MlPWV2FPT0WU
NCI-H1666	NGG2cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nEb2lEPTB;MT64NFk1QCEQvF2=	MVXTRW5ITVJ?
TE-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LsfGlEPTB;MT64NVQ4PSEQvF2=	Ml;6V2FPT0WU
CAL-12T	NY\COm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwOEi5OFUh\|ryP	MnHnV2FPT0WU
TE-8	NWrzbpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PpOmlEPTB;MT65NVM4PyEQvF2=	NYLVepdXW0GQR1XS
KYSE-270	NHTwXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[1[3ZGUUN3ME2yMlAzPzN{IN88US=>	MXrTRW5ITVJ?
GMS-10	M4j6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIqzUZpKSzVyPUKuNFM2OTdizszN	MYHTRW5ITVJ?
A2780	M1e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTOS4p2UUN3ME2yMlA3Ojl2IN88US=>	M4e1OXNCVkeHUh?=
OMC-1	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJwMEixOlkh\|ryP	Mlf1V2FPT0WU
LoVo	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7XXGdJUUN3ME2yMlExPzl5IN88US=>	NXS5fHNSW0GQR1XS
PANC-03-27	NILze2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJwMU[2N\|Eh\|ryP	NXLjZYFxW0GQR1XS
MDA-MB-157	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJwMkG4Nlgh\|ryP	MofYV2FPT0WU
CaR-1	NHfZWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PhVWlEPTB;Mj6yPFI5OSEQvF2=	MV\TRW5ITVJ?
769-P	M3rseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjGTWM2OD1{LkK5NFM4KM7:TR?=	NY\rXnBnW0GQR1XS
NB7	NEjzc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGD5eIhKSzVyPUKuNlk3PzZizszN	NHzKdGdUSU6JRWK=
MKN7	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmCzTWM2OD1{LkO1N\|M2KM7:TR?=	M2\QbXNCVkeHUh?=
NCI-H1048	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWW0WlJXUUN3ME2yMlQ6OTV6IN88US=>	Mm[wV2FPT0WU
RCM-1	NIDxfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrXTWM2OD1{LkWyPVM5KM7:TR?=	NWTYS2U5W0GQR1XS
HT55	NILCXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NES4dXBKSzVyPUKuOVc{QCEQvF2=	NVvrZ25pW0GQR1XS
HCC1569	M3S0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjYZotKSzVyPUKuOVgzQTdizszN	MWPTRW5ITVJ?
LXF-289	M4TiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJwNkO1OlUh\|ryP	M3PSNnNCVkeHUh?=
OVCAR-3	NIfGellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLGTWM2OD1{Lk[3NVY4KM7:TR?=	M4XYVHNCVkeHUh?=
TE-10	NEj6fIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDoXWZKSzVyPUKuOlgxPzhizszN	MkG0V2FPT0WU
SNU-C2B	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJwNki2NVYh\|ryP	NUiw[I84W0GQR1XS
LB1047-RCC	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zLO2lEPTB;Mj63OFg5QCEQvF2=	MWfTRW5ITVJ?
SN12C	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnezTWM2OD1{LkmxPVY1KM7:TR?=	M4niUHNCVkeHUh?=
786-0	NFLnT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPX[JlKSzVyPUOuNFY1ODhizszN	MlexV2FPT0WU
HT-29	NGPNPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTwVphiUUN3ME2zMlA4OzB7IN88US=>	MoS1V2FPT0WU
RPMI-7951	M1zMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;KbHo5UUN3ME2zMlA4PTlizszN	NGfyZZVUSU6JRWK=
NBsusSR	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HONGlEPTB;Mz6xPFI2PCEQvF2=	NVvke4lqW0GQR1XS
NKM-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTNwMUi3OFQh\|ryP	M2TH[XNCVkeHUh?=
Capan-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqwcFVDUUN3ME2zMlQ3QDd3IN88US=>	MoHZV2FPT0WU
MKN1	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTNwNEexNFgh\|ryP	NVSz[o9JW0GQR1XS
OAW-42	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET6bWdKSzVyPUOuOVAxOjZizszN	M{nKZ3NCVkeHUh?=
SKG-IIIa	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXWcppIUUN3ME2zMlUzOjN5IN88US=>	MYTTRW5ITVJ?
no-11	M4TyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTNwNUO1OlQh\|ryP	MlTpV2FPT0WU
NY	M4HWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHDTWM2OD1\|LkWzOlU2KM7:TR?=	MoW5V2FPT0WU
HEC-1	NUHvO3cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[4RnFzUUN3ME2zMlU5QTVizszN	NWfNSnhiW0GQR1XS
NCI-H441	M1qyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDuTWM2OD1\|LkW5PFQyKM7:TR?=	M1fVRnNCVkeHUh?=
NCI-H2009	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXKTWM2OD1\|Lk[xNlE3KM7:TR?=	M2TMXHNCVkeHUh?=
T47D	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7mTWM2OD1\|Lk[yNlE4KM7:TR?=	Mmr5V2FPT0WU
SNU-449	NVXBTIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DLSGlEPTB;Mz62OVgzPiEQvF2=	NWrSTo06W0GQR1XS
NCI-SNU-1	NEP1e\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvadFJKSzVyPUOuOlk4OzVizszN	MmXzV2FPT0WU
BT-20	M3r3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTNwNkm3PVUh\|ryP	M1P3WHNCVkeHUh?=
LS-123	M2PVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTsTWM2OD1\|Lke0Nlg1KM7:TR?=	MmXkV2FPT0WU
8305C	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:xRYh2UUN3ME2zMlc2QTFzIN88US=>	M4\oc3NCVkeHUh?=
OCUB-M	NHHod3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17Rb2lEPTB;Mz63OlE5PyEQvF2=	MljzV2FPT0WU
KOSC-2	NYPvUGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3qTWM2OD1\|LkizOFUyKM7:TR?=	MnGwV2FPT0WU
NCI-H1693	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf6TWM2OD1\|Lki0NVgyKM7:TR?=	MYDTRW5ITVJ?
TE-9	NELSUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXzTWM2OD1\|Lki0N\|gzKM7:TR?=	NGj1W5hUSU6JRWK=
MV-4-11	MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTNwOEe5PVQh\|ryP	MW\TRW5ITVJ?
GAMG	M37VWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKwTWM2OD1\|LkmxN\|E1KM7:TR?=	NXfEPXVQW0GQR1XS
KNS-62	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1e1fGlEPTB;Mz65OFc{OSEQvF2=	M3;6W3NCVkeHUh?=
MC116	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTNwOUW0PFkh\|ryP	NFzt[4tUSU6JRWK=
647-V	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M174WmlEPTB;Mz65PFQ2OiEQvF2=	NGS4TmhUSU6JRWK=
U-87-MG	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfETWM2OD12LkGwOFgyKM7:TR?=	MXvTRW5ITVJ?
RPMI-8226	M1nxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XzcmlEPTB;ND6xNVY{OSEQvF2=	MX7TRW5ITVJ?
SW1417	NXnP[3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTRwMUKxOFch\|ryP	NXLNSZhvW0GQR1XS
LAMA-84	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjxd\|EzUUN3ME20MlE4ODJizszN	NEHBSplUSU6JRWK=
LS-513	NHzWN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHiPHpNUUN3ME20MlMyOjF5IN88US=>	MYXTRW5ITVJ?
KLE	M{DY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTRwNEC4NVkh\|ryP	MXjTRW5ITVJ?
HCT-116	NUPX[ploT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Hm[WlEPTB;ND60NVAxPyEQvF2=	MlTUV2FPT0WU
EPLC-272H	NYnYPFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTRwNEG1N\|Mh\|ryP	M1LV[nNCVkeHUh?=
KS-1	NUfROnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;TV3RKSzVyPUSuOVA5QDlizszN	M3u5T3NCVkeHUh?=
HT-1197	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTRwNUK2Olkh\|ryP	MkHCV2FPT0WU
LCLC-97TM1	NFfYVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrqTWM2OD12LkWzOlg3KM7:TR?=	NF3icIJUSU6JRWK=
ES5	M3n0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTRwOEO3NlMh\|ryP	MmPlV2FPT0WU
CTB-1	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTRwOES4PEDPxE1?	MlXVV2FPT0WU
HL-60	NWm3UIFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHxTWM2OD12Lki2OlEyKM7:TR?=	NH:4bmlUSU6JRWK=
VM-CUB-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnCfYRnUUN3ME20Mlg3QDF7IN88US=>	NI\mNHdUSU6JRWK=
MEG-01	NHPiZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzr[YJKSzVyPUSuPVk1ODNizszN	MYPTRW5ITVJ?
KYSE-520	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{SwSGlEPTB;NT6yNFg{QSEQvF2=	NHvJSmJUSU6JRWK=
HuO-3N1	NYLMRVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD2TWM2OD13LkK0NFQ{KM7:TR?=	MmDlV2FPT0WU
SW620	NWHDZZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PvT2lEPTB;NT6yOFk3PCEQvF2=	Mon1V2FPT0WU
U031	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVe2NlBYUUN3ME21MlI2PDJ2IN88US=>	MW\TRW5ITVJ?
TE-5	M4n4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO3bnNqUUN3ME21MlQxQDVizszN	NILaNFNUSU6JRWK=
NCI-H747	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzzcFVzUUN3ME21MlQzPDd{IN88US=>	NIjMdIpUSU6JRWK=
MG-63	NYTDVJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L3bWlEPTB;NT60PFc3OiEQvF2=	MmfFV2FPT0WU
HC-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTVwNUG4N\|kh\|ryP	MYPTRW5ITVJ?
HCC2998	NVziSG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;PVGlEPTB;NT61NlYyPSEQvF2=	M1jLRnNCVkeHUh?=
NTERA-S-cl-D1	NGr5VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3QOnhJUUN3ME21MlU1PTN5IN88US=>	M{nQOnNCVkeHUh?=
KINGS-1	NVTMW3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13RV2lEPTB;NT62NFk1PCEQvF2=	NEi1XnlUSU6JRWK=
D-423MG	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn4eHNyUUN3ME21MlYyPzB3IN88US=>	MUTTRW5ITVJ?
SW962	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn74TWM2OD13Lk[yNFMzKM7:TR?=	NUn4bpY{W0GQR1XS
LOXIMVI	NHPFb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOxTWM2OD13Lk[zPFc{KM7:TR?=	M4Dxd3NCVkeHUh?=
LS-411N	M1;mZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3OOHNuUUN3ME21Mlc6PDRzIN88US=>	NX3Pb28{W0GQR1XS
NCI-H2291	M{DGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH0bYlKSzVyPUWuPVg6PDNizszN	NFjScnBUSU6JRWK=
A549	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTZwMUK1OVMh\|ryP	MnjSV2FPT0WU
LS-1034	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTZwMkC3NFYh\|ryP	MkLrV2FPT0WU
NB14	M3vtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD5N2hKSzVyPU[uOFM5OzZizszN	MWXTRW5ITVJ?
NCI-H1299	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTZwNkOxO\|Eh\|ryP	NX\jOol[W0GQR1XS
BT-549	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3lcllKSzVyPU[uOlY5QDlizszN	MoroV2FPT0WU
J-RT3-T3-5	M1nMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv1ZYtKSzVyPU[uPFY6KM7:TR?=	NX3LfWNwW0GQR1XS
SW756	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTxTWM2OD14LkmxNVc3KM7:TR?=	NU\BZ2x1W0GQR1XS
DJM-1	NYDVOmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTZwOUKwNVIh\|ryP	NGDqZmxUSU6JRWK=
GP5d	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfmUnRKSzVyPU[uPVc{QTRizszN	NGT3VW9USU6JRWK=
MOLT-4	NW\uU5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH6yPWdKSzVyPUeuNFIyOzVizszN	NXHVSo9EW0GQR1XS
NCI-H28	NI\y[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{e3WGlEPTB;Nz6xOlQxPSEQvF2=	NHzhZ45USU6JRWK=
MN-60	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknXTWM2OD15LkK4NFg6KM7:TR?=	MYHTRW5ITVJ?
RMG-I	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTdwM{myPVYh\|ryP	NGrKZ2xUSU6JRWK=
COLO-800	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDWTWM2OD15LkSxOFQ3KM7:TR?=	NFPkbnZUSU6JRWK=
DB	NVv2bnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGWxZ\|RKSzVyPUeuOlExODVizszN	NV3Cd2lZW0GQR1XS
Ca-Ski	NGrwcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH70[5FKSzVyPUeuOlQzPTlizszN	MX3TRW5ITVJ?
HEL	NIDlbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7adJZtUUN3ME23MlcyOjB\|IN88US=>	M{juW3NCVkeHUh?=
NH-12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPmTWM2OD15LkeyPFA5KM7:TR?=	M4rqVHNCVkeHUh?=
LB373-MEL-D	NUHSdXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHRTWM2OD15Lke2O\|cyKM7:TR?=	M3qwTnNCVkeHUh?=
SW900	M1Oy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfDR5VJUUN3ME23MlgzOTJzIN88US=>	M1GzdnNCVkeHUh?=
JVM-3	NWTy[WJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXWTWM2OD15Lki5OVk6KM7:TR?=	M1rnbnNCVkeHUh?=
OAW-28	M1nuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTudFJKSzVyPUeuPVQ2PzhizszN	NX3OXWI3W0GQR1XS
KURAMOCHI	M4D3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LPTmlEPTB;Nz65OFgyOSEQvF2=	NXXWXYZkW0GQR1XS
BE-13	NX7iTnVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPmUWpKSzVyPUeuPVgyOTJizszN	NYLpeJBoW0GQR1XS
VMRC-RCZ	NUPqN3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPVSZBKSzVyPUiuNFE3QTdizszN	M{TlfXNCVkeHUh?=
NCI-H727	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\ZV2lEPTB;OD6xNFQzKM7:TR?=	M3e2OnNCVkeHUh?=
SW1710	M1HnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHCdY1KSzVyPUiuNVg2OTVizszN	NVLyVpR5W0GQR1XS
D-502MG	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHJbodKSzVyPUiuNlkzQDJizszN	MmHSV2FPT0WU
NCI-H1993	M{SwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HLVGlEPTB;OD6zN\|Y{OSEQvF2=	MYXTRW5ITVJ?
SCC-4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLPTWM2OD16LkS0NFU6KM7:TR?=	MWLTRW5ITVJ?
HAL-01	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:3fHlKSzVyPUiuOVE6OSEQvF2=	NWDJenZvW0GQR1XS
GT3TKB	NYXJW4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkG4TWM2OD16Lk[3PVY1KM7:TR?=	MXvTRW5ITVJ?
SK-OV-3	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGi4TIJKSzVyPUiuO\|E{OjlizszN	NF;QV\|dUSU6JRWK=
COLO-829	NFjmbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRThwOEC5O\|Yh\|ryP	NEHEOVJUSU6JRWK=
OCI-AML2	M4TLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRThwOUW0PFEh\|ryP	M2qwOXNCVkeHUh?=
OS-RC-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX0R2NKSzVyPUmuNFIyQSEQvF2=	NYq5XphuW0GQR1XS
BFTC-909	NXnSSlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1q4V2lEPTB;OT6wOlc6QSEQvF2=	NFjCcWZUSU6JRWK=
EW-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2W1SGlEPTB;OT6xO\|Y2OyEQvF2=	M3TkSXNCVkeHUh?=
HCE-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TqdGlEPTB;OT6yNVU2QCEQvF2=	NGHMfHNUSU6JRWK=
BALL-1	M{fiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTlwMkG5NFch\|ryP	M1GwZnNCVkeHUh?=
SF539	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTlwMkO1OlIh\|ryP	NVzwWlVZW0GQR1XS
CAMA-1	NFKxUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj0[JJNUUN3ME25MlI5OTJ6IN88US=>	M33YcHNCVkeHUh?=
C32	NYDPXI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkG0TWM2OD17LkOzNFY1KM7:TR?=	M{O5RXNCVkeHUh?=
NCI-H1703	NIf6RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTlwM{SzO\|Uh\|ryP	MXvTRW5ITVJ?
NCI-H1650	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LPZWlEPTB;OT62NFk1PiEQvF2=	M4Hi[3NCVkeHUh?=
NCI-H1563	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\KWI5KSzVyPUmuO\|YxOzFizszN	M1LzSHNCVkeHUh?=
CAL-85-1	NVrnPWM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LCUGlEPTB;OT64O\|M5OyEQvF2=	M1fhSHNCVkeHUh?=
UM-UC-3	M3S4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHJWFh2UUN3ME25Mlk2ODNizszN	MV\TRW5ITVJ?
BxPC-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFyLkC5O\|Ih\|ryP	NEiyOopUSU6JRWK=
MHH-PREB-1	NWPtVm1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFyLkG5PVkh\|ryP	NEW1eGpUSU6JRWK=
DEL	M3zOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DCTmlEPTB;MUCuN\|k1PiEQvF2=	MlSzV2FPT0WU
HuCCT1	NEW1dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPGN4h5UUN3ME2xNE43ODN\|IN88US=>	M4XmNXNCVkeHUh?=
OVCAR-4	NVPYNGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi4UGF7UUN3ME2xNE45QDN3IN88US=>	NYTEO5JLW0GQR1XS
CAL-72	NIXWW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\CfFRKSzVyPUGwMlk{QTFizszN	MXTTRW5ITVJ?
HCC1954	M4ThTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHGNFhKSzVyPUGxMlA4PTRizszN	M1PHRnNCVkeHUh?=
EFO-21	Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfuVYJJUUN3ME2xNU4yODR3IN88US=>	Ml[5V2FPT0WU
FTC-133	M3HIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKyTWM2OD1zMT6xOFA4KM7:TR?=	M3zEXnNCVkeHUh?=
SK-MEL-24	NFfHTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPyTWM2OD1zMT6yN\|Y3KM7:TR?=	MULTRW5ITVJ?
UACC-62	NWLVUYxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;TTWM2OD1zMT6yN\|Y5KM7:TR?=	M1jPeXNCVkeHUh?=
NCI-H650	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjUR3hKSzVyPUGxMlI1OThizszN	NXS4cZdJW0GQR1XS
ALL-PO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrHTVFUUUN3ME2xNU4zPTF{IN88US=>	MkX6V2FPT0WU
T84	NVLrUY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFzLkO5NFch\|ryP	NGLzeIFUSU6JRWK=
IST-MEL1	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LhdWlEPTB;MUGuOFU2QSEQvF2=	NH\JT5lUSU6JRWK=
SW626	NX:0Z\|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjUXVNKSzVyPUGxMlU4PTVizszN	M{LmdXNCVkeHUh?=
RPMI-2650	NXvKV2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v5RmlEPTB;MUGuOVg5PSEQvF2=	M1i2eXNCVkeHUh?=
MC-IXC	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYS5TW9CUUN3ME2xNU43PzJ6IN88US=>	NF;zNGdUSU6JRWK=
HOP-62	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj0TWM2OD1zMT62O\|Y1KM7:TR?=	NH\Td5pUSU6JRWK=
NOS-1	NGrWbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn32TWM2OD1zMT63NVA6KM7:TR?=	NEXzem9USU6JRWK=
SW1573	M2\uOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\6eXdKSzVyPUGxMlczQTVizszN	MXHTRW5ITVJ?
WM-115	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z6[mlEPTB;MUGuO\|U5QCEQvF2=	M2DZXnNCVkeHUh?=
HuO9	NHXLW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFzLki3O\|Qh\|ryP	NHHpfJZUSU6JRWK=
YAPC	NHfKbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfFTWM2OD1zMT65NlU6KM7:TR?=	NVT0SIxFW0GQR1XS
MDA-MB-453	NYi1OJVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTMXI1KSzVyPUGxMlk2OTVizszN	MUjTRW5ITVJ?
NCI-H596	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYqxTHEyUUN3ME2xNk4xOzZ7IN88US=>	NFfwVpRUSU6JRWK=
A172	NYLWNpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnQc2pKSzVyPUGyMlA4QThizszN	NIXTT4dUSU6JRWK=
RS4-11	NHvC[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknITWM2OD1zMj6xO\|I2KM7:TR?=	MXrTRW5ITVJ?
HCC1937	M1fGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjlZXVKSzVyPUGyMlc2PjRizszN	MnKxV2FPT0WU
SW837	M4K1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjoOYVKSzVyPUGyMlkxOjhizszN	NIfORnRUSU6JRWK=
NMC-G1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jIN2lEPTB;MUKuPVI{PCEQvF2=	NYDxWWJrW0GQR1XS
PFSK-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDPTWM2OD1zMz6wOkDPxE1?	MXfTRW5ITVJ?
DBTRG-05MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfwT45KSzVyPUGzMlA3OzJizszN	NHO3NXJUSU6JRWK=
SK-UT-1	NXjSTmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHifVZKSzVyPUGzMlExQDNizszN	MWXTRW5ITVJ?
OVCAR-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrlTWM2OD1zMz6xOVk{KM7:TR?=	NYS5OFFNW0GQR1XS
8505C	NGPLemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLRTWM2OD1zMz6yNFY4KM7:TR?=	NInQepBUSU6JRWK=
SK-MEL-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M361b2lEPTB;MUOuO\|E{PSEQvF2=	MUjTRW5ITVJ?
LK-2	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvHTWM2OD1zMz63OlM6KM7:TR?=	MWnTRW5ITVJ?
OE33	M3zHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLQUnpRUUN3ME2xN{44QDZizszN	NEex[ndUSU6JRWK=
Ramos-2G6-4C10	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfw[4JKSzVyPUG0MlAzODJizszN	MlrCV2FPT0WU
EW-13	NHXtc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXXN25KSzVyPUG0MlA{PTJizszN	NHHBU45USU6JRWK=
NCI-H1793	M1TleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Xwb2lEPTB;MUSuNlA5PyEQvF2=	NF7HT3dUSU6JRWK=
BHT-101	NEHrdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF2LkK0NUDPxE1?	M2HlSXNCVkeHUh?=
RKO	M3zMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrkc4JKSzVyPUG0MlUxPzVizszN	MVPTRW5ITVJ?
NEC8	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjjTWM2OD1zND61OFczKM7:TR?=	NVzFNlZqW0GQR1XS
PANC-10-05	M{nyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTF2Lk[yOFch\|ryP	MX7TRW5ITVJ?
NCI-H2030	NWPBTotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTF2Lk[0OFgh\|ryP	M{jrXnNCVkeHUh?=
C2BBe1	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDKR2RKSzVyPUG0Mlc3PCEQvF2=	NW\IeJFRW0GQR1XS
EM-2	M3niemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{O0UmlEPTB;MUSuPFU4PiEQvF2=	NYOwdHRTW0GQR1XS
HCC1395	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nzbmlEPTB;MUSuPVM{QCEQvF2=	MW\TRW5ITVJ?
A2058	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHUXIlGUUN3ME2xOU4xPDB7IN88US=>	MXvTRW5ITVJ?
SW1463	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorLTWM2OD1zNT6wOFg2KM7:TR?=	Mle2V2FPT0WU
J82	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTF3LkC1O{DPxE1?	M{HzUXNCVkeHUh?=
CAL-120	Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjxR4JKSzVyPUG1MlE1PDdizszN	Mly2V2FPT0WU
COLO-824	M1fF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDyWWw3UUN3ME2xOU4yPTd7IN88US=>	NIfBcmhUSU6JRWK=
LNCaP-Clone-FGC	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7lTWM2OD1zNT60NlQ5KM7:TR?=	NHjnVWdUSU6JRWK=
CP66-MEL	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DhOGlEPTB;MUWuOFY5QCEQvF2=	MnvYV2FPT0WU
OC-314	M3[y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jJNWlEPTB;MUWuOFcyPCEQvF2=	NGrjSZZUSU6JRWK=
OVCAR-8	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILC[2ZKSzVyPUG1Mlg5PjFizszN	NIHT[W9USU6JRWK=
MFE-280	MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\ybYZDUUN3ME2xOk4xPDh6IN88US=>	M3rJNnNCVkeHUh?=
MHH-NB-11	M3zmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTYdmFKSzVyPUG2MlA5OzlizszN	M2DOcHNCVkeHUh?=
SW1990	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW4NJFQUUN3ME2xOk4yPzV3IN88US=>	M3H0XXNCVkeHUh?=
U-266	NGfLO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTlTWM2OD1zNj6yNlk6KM7:TR?=	M1z2THNCVkeHUh?=
MFM-223	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLUTWM2OD1zNj6zPVY2KM7:TR?=	MnG2V2FPT0WU
L-363	M4LhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfwTYZKSzVyPUG2MlQ2PzdizszN	NHLNWYdUSU6JRWK=
MCF7	M3fPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3HOFVKSzVyPUG2MlQ4OjNizszN	MmDlV2FPT0WU
SK-MEL-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6yZoRKSzVyPUG2MlQ4QDdizszN	NELkO2xUSU6JRWK=
HH	NXO3PWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTF4LkWxOlIh\|ryP	M3GzfnNCVkeHUh?=
no-10	NIrEN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1X5RmlEPTB;MU[uOlM1OyEQvF2=	M{PXTXNCVkeHUh?=
HuP-T3	NUjXc\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPSNoxVUUN3ME2xOk43PTd4IN88US=>	MlHUV2FPT0WU
QIMR-WIL	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTF4LkexNFUh\|ryP	M3iyUXNCVkeHUh?=
NCI-H1092	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTF4LkizNVYh\|ryP	M4LkfXNCVkeHUh?=
MZ2-MEL	NEHNdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr6N4h6UUN3ME2xOk45PDB\|IN88US=>	MknGV2FPT0WU
ES3	NYi3XXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17BZ2lEPTB;MU[uPVE{PCEQvF2=	MYHTRW5ITVJ?
COLO-684	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nwUWlEPTB;MU[uPVQ4PyEQvF2=	MlzaV2FPT0WU
NCI-H661	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF4Lkm2PVQh\|ryP	NWPpVZN4W0GQR1XS
CP50-MEL-B	M3;2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHJTWM2OD1zNz6wN\|Q{KM7:TR?=	MXLTRW5ITVJ?
NCI-H2405	NVr3TFNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli4TWM2OD1zNz6xPVc1KM7:TR?=	NUfwPIJKW0GQR1XS
U-2-OS	M17I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF5LkWzNFch\|ryP	MnPWV2FPT0WU
RERF-LC-MS	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C2cGlEPTB;MUeuOVUxQCEQvF2=	MWHTRW5ITVJ?
NCI-H2342	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfNWWlKSzVyPUG3MlU2PyEQvF2=	MWjTRW5ITVJ?
ES8	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1foXGlEPTB;MUeuOlA5PyEQvF2=	M17BWHNCVkeHUh?=
MOLT-16	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHVXnJ{UUN3ME2xO{45QTN2IN88US=>	NU\pXGpKW0GQR1XS
RH-18	NWDSdWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF6LkCwN\|Uh\|ryP	NXnnfHYxW0GQR1XS
D-283MED	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHMR\|dzUUN3ME2xPE4xODh6IN88US=>	MVzTRW5ITVJ?
RCC10RGB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTF6LkC1OVkh\|ryP	Mk[3V2FPT0WU
NCI-H1437	NXf6cnB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfUelRKSzVyPUG4MlE3PDFizszN	MljFV2FPT0WU
SW982	NGXiVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnwSXZKSzVyPUG4MlI3PzFizszN	M4nmSnNCVkeHUh?=
IST-MES1	M3q3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\2U2J1UUN3ME2xPE41PDJ6IN88US=>	NH3qRW9USU6JRWK=
A704	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHzN21ZUUN3ME2xPE41PzV\|IN88US=>	NGPob\|JUSU6JRWK=
ESS-1	NXuzXpg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M361N2lEPTB;MUiuOVIxPSEQvF2=	NYD0epF6W0GQR1XS
SCH	NXS4TFZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PTdGlEPTB;MUiuOlQ2PiEQvF2=	NULOd2RvW0GQR1XS
COLO-320-HSR	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL3b2JKSzVyPUG4Mlc1PiEQvF2=	M3rHcHNCVkeHUh?=
Mo-T	M3;aNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fYcGlEPTB;MUiuPFIxPCEQvF2=	NHG2dYtUSU6JRWK=
Saos-2	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3JWnp6UUN3ME2xPU4yOTZ{IN88US=>	NF:2N41USU6JRWK=
SW684	NUPWSlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33kfGlEPTB;MUmuNVMzPiEQvF2=	NYjnOnVtW0GQR1XS
KMOE-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Tt[GlEPTB;MUmuNlI1OiEQvF2=	MXvTRW5ITVJ?
MMAC-SF	M4DSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjxN5BKUUN3ME2xPU4zPjB5IN88US=>	Mm\IV2FPT0WU
JAR	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;iPWk2UUN3ME2xPU4zQTlizszN	M{DReXNCVkeHUh?=
SK-MEL-28	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF7LkOzOlMh\|ryP	NUOwW213W0GQR1XS
KNS-81-FD	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTF7LkW0Olgh\|ryP	NVy0VWd{W0GQR1XS
ES7	M{Dw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTF7Lk[yPVIh\|ryP	NWDFRmkyW0GQR1XS
AsPC-1	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXuTWM2OD1zOT62OFcyKM7:TR?=	MYPTRW5ITVJ?
NCI-H1155	NEnBUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;UO5EzUUN3ME2xPU44OjN6IN88US=>	M2Gwc3NCVkeHUh?=
KYSE-510	M3XCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK0TWM2OD1zOT64O\|Q5KM7:TR?=	MYDTRW5ITVJ?
ES1	NHrq[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTF7LkmyNVMh\|ryP	MVzTRW5ITVJ?
PC-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f6XGlEPTB;MUmuPVYxPCEQvF2=	MYnTRW5ITVJ?
GCT	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fTZWlEPTB;MkCuN\|AzPiEQvF2=	MmnkV2FPT0WU
KARPAS-299	NGf0cm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvKV3dKSzVyPUKwMlM1OjJizszN	Mk\LV2FPT0WU
DOHH-2	NXnjOXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq0T3RzUUN3ME2yNE42PDZ\|IN88US=>	MVvTRW5ITVJ?
COLO-741	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJyLk[2JO69VQ>?	NHjWc3lUSU6JRWK=
NCI-H1395	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJyLk[2PVch\|ryP	NWXKWmxEW0GQR1XS
HCC1187	M{HSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfXU2dKSzVyPUKwMlY4OzRizszN	M3m5dHNCVkeHUh?=
Becker	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTJyLkeyNFEh\|ryP	NUDkXWtRW0GQR1XS
LU-134-A	M1PWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDBTWM2OD1{MT6xNFI3KM7:TR?=	M{XRRnNCVkeHUh?=
MKN45	NFq5NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fxWGlEPTB;MkGuNVU2OSEQvF2=	NIXOUodUSU6JRWK=
LC-2-ad	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL1bpdCUUN3ME2yNU4zPzJ7IN88US=>	M3j3bXNCVkeHUh?=
EW-24	M3z5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnniTWM2OD1{MT6zPVQ2KM7:TR?=	NWXteXZtW0GQR1XS
SK-N-AS	NU\Lem97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHOTWM2OD1{MT64Nlc3KM7:TR?=	MWXTRW5ITVJ?
NCI-H2052	NYS3cm51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHXe3VKSzVyPUKxMlg6PjNizszN	MWPTRW5ITVJ?
A4-Fuk	NHLRTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDVcI9oUUN3ME2yNk4yPDF7IN88US=>	NY\JdXk2W0GQR1XS
NB10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fiOGlEPTB;MkKuNlM4OSEQvF2=	M2HTT3NCVkeHUh?=
CHP-212	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJ{LkOyNlIh\|ryP	NHPpXlZUSU6JRWK=
KM12	NHzsOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLsTWM2OD1{Mj6zOVYh\|ryP	MYTTRW5ITVJ?
JEG-3	M2W0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzEVoZsUUN3ME2yNk4{PzhizszN	MUXTRW5ITVJ?
LN-405	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfXWXNKSzVyPUKyMlU6OTNizszN	MUPTRW5ITVJ?
HCT-15	NFPU[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf4TZBKSzVyPUKyMlc1PDFizszN	NIjpR2xUSU6JRWK=
MLMA	M4K2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jtNGlEPTB;MkKuO\|Q4KM7:TR?=	MUnTRW5ITVJ?
GI-1	NEfBWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPMe4tKSzVyPUKyMlc3PThizszN	NFH2RnlUSU6JRWK=
RT-112	NEHrXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ{Lki2NVYh\|ryP	NFLH[m1USU6JRWK=
MPP-89	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX33ZY1jUUN3ME2yNk45PjZzIN88US=>	MoPRV2FPT0WU
A3-KAW	NFflTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnIWHVEUUN3ME2yN{4yODB\|IN88US=>	MlvvV2FPT0WU
KALS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjITWM2OD1{Mz6xOFE1KM7:TR?=	Ml;sV2FPT0WU
SF126	NHfyeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK0[WZKSzVyPUKzMlY6OjRizszN	MlvxV2FPT0WU
SiHa	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TH[WlEPTB;MkOuPVMzPyEQvF2=	NILtToRUSU6JRWK=
MDA-MB-415	M3zidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\EcllKSzVyPUKzMlk1QTlizszN	NIi1dYhUSU6JRWK=
Daoy	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDWTWM2OD1{ND6xNlYh\|ryP	NX\kZpFpW0GQR1XS
COR-L23	NVrQ[IZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXoU3dKSzVyPUK0MlE4PjdizszN	NWDScpFbW0GQR1XS
KG-1	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJ2LkG5Nlgh\|ryP	M3fjenNCVkeHUh?=
L-428	NVTYd\|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{H1T2lEPTB;MkSuOVc6OSEQvF2=	MlziV2FPT0WU
NCI-H520	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7DclZKSzVyPUK0Mlg5PjFizszN	M1XLUHNCVkeHUh?=
COLO-792	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL3PWVKSzVyPUK1MlI4OzJizszN	NF;yNIVUSU6JRWK=
NB12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPS[ldEUUN3ME2yOU4zQTR5IN88US=>	NH7uWIRUSU6JRWK=
GAK	M1f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDSbnhKSzVyPUK1MlI6PjNizszN	M3yycnNCVkeHUh?=
SW780	NV;0NlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm3TWM2OD1{NT6zNlY1KM7:TR?=	NYPRdZg{W0GQR1XS
GB-1	NX6wcVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r2RWlEPTB;MkWuOFA3QSEQvF2=	M{jOZXNCVkeHUh?=
P12-ICHIKAWA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:0UmlEPTB;MkWuOFc5PSEQvF2=	NYLidHozW0GQR1XS
NCI-H1651	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1raXWlEPTB;MkWuOVk4KM7:TR?=	M1ToTXNCVkeHUh?=
KE-37	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHqTWM2OD1{NT63N\|E2KM7:TR?=	MYPTRW5ITVJ?
CCRF-CEM	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJ3Lkm2O{DPxE1?	MWrTRW5ITVJ?
SF295	NF65TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTZcIxzUUN3ME2yOk4xPDJ3IN88US=>	MknqV2FPT0WU
G-361	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTJ4LkGwNlch\|ryP	MVrTRW5ITVJ?
HOP-92	M1e1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPnVIxKSzVyPUK2MlEzOjZizszN	MVXTRW5ITVJ?
UMC-11	M322O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XYbmlEPTB;Mk[uOFUyPCEQvF2=	NUfLUGhrW0GQR1XS
IST-SL1	NXrwWnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTJ4Lk[1PVEh\|ryP	MYTTRW5ITVJ?
TE-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ4Lke3OVIh\|ryP	NHLnRZJUSU6JRWK=
NCI-H1304	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHGwTnlKSzVyPUK2MlkyODhizszN	Ml;mV2FPT0WU
SJSA-1	NHrZNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PVSmlEPTB;MkeuNFE4PiEQvF2=	MkXaV2FPT0WU
BCPAP	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPPTWM2OD1{Nz6xN\|ch\|ryP	NHXsZ4pUSU6JRWK=
HTC-C3	M3vJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJ5LkK1OlEh\|ryP	M3PvfHNCVkeHUh?=
EW-16	NYjhcVZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJ5LkK5OFch\|ryP	M3L2XXNCVkeHUh?=
HT-144	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HKPGlEPTB;MkeuOFA{OiEQvF2=	NU\QWnZnW0GQR1XS
MHH-ES-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLldY1KSzVyPUK3MlQ1PDdizszN	MnW5V2FPT0WU
T98G	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfWTWM2OD1{Nz61PFQ3KM7:TR?=	MWPTRW5ITVJ?
RPMI-8866	NE\j[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWm1UXZXUUN3ME2yO{44PTZ{IN88US=>	NHPRSI9USU6JRWK=
BEN	M3zNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTJ5Lki1NVch\|ryP	MorxV2FPT0WU
MDA-MB-231	NXG2N5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDDTWM2OD1{OD6yO\|k2KM7:TR?=	MoHuV2FPT0WU
HuH-7	NFPoWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P2TmlEPTB;MkiuOFAzQCEQvF2=	NFvjTldUSU6JRWK=
SK-N-FI	MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJ6LkSzN{DPxE1?	NYW1[3U5W0GQR1XS
AN3-CA	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGT3fFdKSzVyPUK4MlQ{QTVizszN	Ml3BV2FPT0WU
EGI-1	NEPBNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLJXZFKSzVyPUK4MlU6OjhizszN	MmnFV2FPT0WU
697	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJ6Lk[zN\|Eh\|ryP	NY\qU3p2W0GQR1XS
TCCSUP	M1TnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnufGUzUUN3ME2yPE43PDF6IN88US=>	NHGwSIhUSU6JRWK=
GR-ST	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPBTpVtUUN3ME2yPE43Pjl4IN88US=>	MXvTRW5ITVJ?
SK-N-DZ	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF22RW5KSzVyPUK4MlY5QDVizszN	M1radXNCVkeHUh?=
MIA-PaCa-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJ6Lke5OVkh\|ryP	MnPJV2FPT0WU
IGR-1	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLkTWM2OD1{OD64PFc1KM7:TR?=	M4TybXNCVkeHUh?=
BFTC-905	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmr1TWM2OD1{OT6yO\|A2KM7:TR?=	M1fqW3NCVkeHUh?=
NCI-H1581	NHeyfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n4[mlEPTB;MkmuN\|E1PSEQvF2=	NGSyd\|hUSU6JRWK=
RD	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jxdmlEPTB;MkmuOVI{OyEQvF2=	MmD3V2FPT0WU
SF268	NHzITHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJ7LkW5N\|Eh\|ryP	M4TmXHNCVkeHUh?=
SHP-77	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTJ7Lk[xPFIh\|ryP	NF7jUXFUSU6JRWK=
D-566MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLNTWM2OD1{OT65N\|k{KM7:TR?=	MX3TRW5ITVJ?
TGBC1TKB	M1zOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\PSXBKSzVyPUOwMlEzOzhizszN	M4fUSXNCVkeHUh?=
MEL-HO	NInGbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmO2TWM2OD1\|MD6xOFI{KM7:TR?=	NWLFUGlNW0GQR1XS
SJRH30	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPlTWM2OD1\|MD6yNVA5KM7:TR?=	NYXqSJQ3W0GQR1XS
D-336MG	NH6z[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEj6NY9KSzVyPUOwMlI5QTJizszN	MorDV2FPT0WU
C3A	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M176b2lEPTB;M{CuNlkzPyEQvF2=	MYrTRW5ITVJ?
Calu-6	NVHUc\|J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEKwR5JKSzVyPUOwMlI6PjNizszN	NWjQWYppW0GQR1XS
MZ1-PC	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO2O2xIUUN3ME2zNE4{QTNizszN	Mn24V2FPT0WU
KYSE-70	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTNyLkWxNVQh\|ryP	NYfUNYhXW0GQR1XS
CAPAN-1	NWCwOW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4WySWlEPTB;M{CuOVE5OSEQvF2=	NHnqcZdUSU6JRWK=
DK-MG	NGTXdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknCTWM2OD1\|MD61OFU3KM7:TR?=	MmiyV2FPT0WU
SK-HEP-1	M2G3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLZTWM2OD1\|MD62N\|I3KM7:TR?=	NFr2T5FUSU6JRWK=
MS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnXTWM2OD1\|MD64PFg6KM7:TR?=	NHvucolUSU6JRWK=
GI-ME-N	M3vBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7zN2VYUUN3ME2zNU4xPTdzIN88US=>	MWjTRW5ITVJ?
NCI-H510A	NWTFZlB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\4fHF{UUN3ME2zNU41ODB4IN88US=>	MWrTRW5ITVJ?
NB17	M2jRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjld5NKSzVyPUOxMlUyQDVizszN	NFrFPI9USU6JRWK=
639-V	NGX2S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\0RWlEPTB;M{GuOVI1OyEQvF2=	NYPLdHFTW0GQR1XS
CAL-51	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XmbWlEPTB;M{GuOVY3PyEQvF2=	NFS5UlJUSU6JRWK=
HGC-27	M4\Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\HTWM2OD1\|MT61PFc{KM7:TR?=	NInrc\|RUSU6JRWK=
GOTO	NUHHcoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmWxTWM2OD1\|MT64OVA3KM7:TR?=	NFG5[4ZUSU6JRWK=
ChaGo-K-1	M{\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\ZTWM2OD1\|Mj6wNFch\|ryP	NGjjN5lUSU6JRWK=
RO82-W-1	MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[5OmlEPTB;M{KuNVYxPCEQvF2=	M4PtVXNCVkeHUh?=
SH-4	NHTQPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELBc4RKSzVyPUOyMlE5PThizszN	Ml3IV2FPT0WU
A204	M1LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f5WGlEPTB;M{KuOVA3QSEQvF2=	NELGTYpUSU6JRWK=
DMS-273	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTN{LkWzNlIh\|ryP	Mo\sV2FPT0WU
KGN	NVr1TGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DBNGlEPTB;M{KuOlM{KM7:TR?=	MlnUV2FPT0WU
SK-MEL-2	MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi3eYtkUUN3ME2zNk43PTJ5IN88US=>	MXLTRW5ITVJ?
NCI-H2228	NE\OemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTN{Lk[2NFIh\|ryP	M1e4TXNCVkeHUh?=
MKN28	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDwUnNGUUN3ME2zNk44QDN6IN88US=>	MYTTRW5ITVJ?
H-EMC-SS	NYPXW\|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPDTWM2OD1\|Mj65Olc5KM7:TR?=	MX\TRW5ITVJ?
ATN-1	NXHS[4JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTN\|LkG0NVYh\|ryP	MUXTRW5ITVJ?
D-263MG	NV\aZ5lET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi4TWM2OD1\|Mz64N\|c5KM7:TR?=	MVnTRW5ITVJ?
LU-135	M37Jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTN\|Lki4Nlkh\|ryP	NUXKXpp5W0GQR1XS
C8166	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TwWGlEPTB;M{OuPFg2PCEQvF2=	NX7hdWN6W0GQR1XS
T-24	NGnFRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTN2LkCyNFUh\|ryP	NFnnUmFUSU6JRWK=
Mewo	M1TVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTN2LkGzOFkh\|ryP	MoPBV2FPT0WU
22RV1	NEjr[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzUTWM2OD1\|ND6xO\|U1KM7:TR?=	MWnTRW5ITVJ?
KM-H2	MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13xS2lEPTB;M{SuNVc4QSEQvF2=	MlW0V2FPT0WU
NCI-H2122	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIi3WZVKSzVyPUO0MlM1PzFizszN	Mlq3V2FPT0WU
ABC-1	M2\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXntZ4Y1UUN3ME2zOE4{Pjl\|IN88US=>	M3uyXnNCVkeHUh?=
NCI-H1355	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jEU2lEPTB;M{SuN\|g5QSEQvF2=	NHXiWJNUSU6JRWK=
NOMO-1	NX:2eWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH62dYNKSzVyPUO0MlU4ODNizszN	MoH5V2FPT0WU
MZ7-mel	NVf1U\|hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDYTWM2OD1\|ND62OFg4KM7:TR?=	NHXQbmxUSU6JRWK=
NCI-H810	NXjMNXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoraTWM2OD1\|ND63Nlc5KM7:TR?=	NGSwTGFUSU6JRWK=
D-392MG	M3XoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTN3LkC1OlUh\|ryP	MlL1V2FPT0WU
LB771-HNC	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHy2W\|RKSzVyPUO1MlE3PThizszN	M1fFZ3NCVkeHUh?=
COLO-679	NWPYcJFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmqwTWM2OD1\|NT6zPFgh\|ryP	MmLDV2FPT0WU
SK-PN-DW	NFnv[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fWXGlEPTB;M{WuOFM3QSEQvF2=	MWPTRW5ITVJ?
VA-ES-BJ	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrhTWM2OD1\|NT60OlQ6KM7:TR?=	M3HJNHNCVkeHUh?=
KNS-42	M2XaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi5TWM2OD1\|NT61PFI3KM7:TR?=	NWHsTWFlW0GQR1XS
RVH-421	NHnL[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXrTWE1UUN3ME2zOU44PjR3IN88US=>	M{C5T3NCVkeHUh?=
P30-OHK	M1LOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zpSmlEPTB;M{WuPFc2OiEQvF2=	NGm1eXFUSU6JRWK=
G-402	M361d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXnTWM2OD1\|NT65PFY4KM7:TR?=	MmXFV2FPT0WU
S-117	NIHhb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPa[\|NKSzVyPUO2MlMxODhizszN	MlHBV2FPT0WU
RXF393	NF;IRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTnbIdHUUN3ME2zOk4{Pzh3IN88US=>	M1rwPHNCVkeHUh?=
LCLC-103H	NG\oUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTN4Lke4NFMh\|ryP	MVnTRW5ITVJ?
U-118-MG	M1K0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;ne2lEPTB;M{[uPFg1PyEQvF2=	M4HG[3NCVkeHUh?=
8-MG-BA	NFPNV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfLTWM2OD1\|Nj65OFg{KM7:TR?=	MX7TRW5ITVJ?
MFH-ino	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7vRlJlUUN3ME2zO{4{OzdzIN88US=>	M1f5UnNCVkeHUh?=
NCI-H23	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13GRmlEPTB;M{euOFE6PiEQvF2=	M362fnNCVkeHUh?=
NCI-H446	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPLTWM2OD1\|Nz60PFYzKM7:TR?=	MX;TRW5ITVJ?
LU-99A	M2jKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1WxZ2lEPTB;M{euOVc{OSEQvF2=	M2XNXnNCVkeHUh?=
KP-N-YN	NVzUdVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfPbGFKSzVyPUO3MlYyQTVizszN	NVfhNYZzW0GQR1XS
SCC-9	NXntRYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljDTWM2OD1\|Nz63PFM5KM7:TR?=	MYTTRW5ITVJ?
EFM-19	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHrZXdMUUN3ME2zO{44QTZ5IN88US=>	MWjTRW5ITVJ?
A427	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTN5LkmxNFch\|ryP	NVrIepJ{W0GQR1XS
LB831-BLC	NUO0ZotsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXf3dpB{UUN3ME2zPE43ODN7IN88US=>	NI\wdmpUSU6JRWK=
HOS	M1XWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHMRYdKSzVyPUO5MlYzPzNizszN	NEfqSHNUSU6JRWK=
LAN-6	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TDbGlEPTB;NECuNFEyOiEQvF2=	M2Lsd3NCVkeHUh?=
U251	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPpTWM2OD12MD60NFU1KM7:TR?=	MVrTRW5ITVJ?
SNU-387	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYC3dWJGUUN3ME20NE41PTV\|IN88US=>	MoHyV2FPT0WU
DMS-79	NXP1NoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTRyLkW4PFkh\|ryP	NX[ydWxZW0GQR1XS
SK-LU-1	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\JZ\|VKSzVyPUSwMlY2PjhizszN	Mn;3V2FPT0WU
HT	NUf3dWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\HW4xKSzVyPUSwMlY3OzlizszN	NIjyV4tUSU6JRWK=
KP-N-YS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYno[lJlUUN3ME20NE43PzZ6IN88US=>	MWTTRW5ITVJ?
DMS-114	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTRyLkizO\|Qh\|ryP	MULTRW5ITVJ?
HUTU-80	NGq4PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXQWoRHUUN3ME20NU4xPTZ7IN88US=>	NWPvRVU6W0GQR1XS
ONS-76	M4nkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfwTWM2OD12MT60O\|A6KM7:TR?=	MUjTRW5ITVJ?
A673	NUnjOpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTRzLkWxOVch\|ryP	NHe1elJUSU6JRWK=
HPAF-II	NFHSc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3vdVI4UUN3ME20NU43PzB7IN88US=>	M3;WcXNCVkeHUh?=
UACC-257	M3j5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEj0RmpKSzVyPUSxMlc{PjlizszN	M3XybXNCVkeHUh?=
EW-22	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nrfGlEPTB;NEGuPFY6PyEQvF2=	MXnTRW5ITVJ?
NCI-H1755	NXH0WHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPZWo1oUUN3ME20NU45PzJ3IN88US=>	NHfHfXlUSU6JRWK=
KYSE-150	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPnTWM2OD12Mj6xO\|gzKM7:TR?=	M2LBO3NCVkeHUh?=
CGTH-W-1	NVnGc4RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXJfXIzUUN3ME20Nk41QTV3IN88US=>	NVrITFhNW0GQR1XS
NB13	NV;5ZXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH6NodKSzVyPUSyMlYzOTdizszN	M1\ObXNCVkeHUh?=
SW872	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jHcGlEPTB;NEKuOlM{OSEQvF2=	M1XPcHNCVkeHUh?=
KP-4	M2LmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfWcJpUUUN3ME20Nk45QDN{IN88US=>	Mk\yV2FPT0WU
HCC38	NI\XSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK5eW57UUN3ME20Nk46PjF6IN88US=>	MmXMV2FPT0WU
BB49-HNC	NEjseW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnaeFhKSzVyPUSzMlI{PTZizszN	MU\TRW5ITVJ?
CAL-62	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofITWM2OD12Mz60NFI5KM7:TR?=	M3HVSXNCVkeHUh?=
NCI-H2029	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3qwS2lEPTB;NEOuOVU5OSEQvF2=	MWPTRW5ITVJ?
M14	M2roe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu1dIJKSzVyPUS0MlE{OzJizszN	MlnvV2FPT0WU
COLO-680N	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTR2LkOzPUDPxE1?	M2f2ZXNCVkeHUh?=
Hs-578-T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHkWnBUUUN3ME20OU4xOjl2IN88US=>	MXXTRW5ITVJ?
MSTO-211H	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTR3Lkm0PFIh\|ryP	MojzV2FPT0WU
EW-1	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTR3Lkm2PFkh\|ryP	NULVcHdHW0GQR1XS
SW948	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLZTWM2OD12Nj60OFYzKM7:TR?=	MUfTRW5ITVJ?
NCI-H460	NGfMOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fLeGlEPTB;NE[uOVI{KM7:TR?=	NV\lWpFrW0GQR1XS
CAS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoS5TWM2OD12Nj63O\|AyKM7:TR?=	NH3KOIRUSU6JRWK=
TGBC11TKB	M3:0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\oTWM2OD12Nz6xO\|c4KM7:TR?=	M1zZPXNCVkeHUh?=
HD-MY-Z	M1zve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonxTWM2OD12OD63PFYh\|ryP	MnjhV2FPT0WU
NCI-H226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2W0[GlEPTB;NEmuO\|c5PSEQvF2=	MmfqV2FPT0WU
PA-1	M1rvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TSeWlEPTB;NEmuPFM{PSEQvF2=	MnXUV2FPT0WU
LB2518-MEL	NXjTfmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XET2lEPTB;NEmuPFczOyEQvF2=	NVLLd3pDW0GQR1XS
A101D	NELWWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj6XVNKSzVyPUS5Mlk1OjVizszN	M2rGU3NCVkeHUh?=
NCI-H2087	NFnOb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3DcHBKSzVyPUS5Mlk3QDJizszN	MoTMV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	850140-72-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04497584	Not yet recruiting	Drug: Afatinib + Prednisone	Advanced Squamous Non Small Cell Lung Cancer	University of Texas Southwestern Medical Center	September 1 2020	Phase 2
NCT04413201	Not yet recruiting	Drug: Afatinib\|Drug: Osimertinib	Non-squamous NSCLC	Michael Hopp\|Boehringer Ingelheim\|Johannes Gutenberg University Mainz	June 30 2020	Phase 4
NCT04206787	Recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 20 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)